查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1439071

暴食症治疗市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按类型、配销通路、地区和竞争细分

Binge-eating Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Distribution Channel, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球暴食症治疗市场价值为 5.7132 亿美元，预计到 2028 年，预测期内将出现令人印象深刻的增长，复合CAGR为7.25%。暴食症(BED) 是一种普遍存在的严重饮食失调症，其特征是反覆出现大量进食，且常伴随缺乏控制。这种心理健康状况影响着全世界数百万人，使其成为公共卫生和医疗保健提供者的重大关切。随着人们对暴食症认识的提高和诊断的更加精确，暴食症治疗的全球市场出现了大幅增长。暴食症不只是暴饮暴食，而是暴饮暴食。这是一种复杂的心理健康状况，会带来许多心理、社会和身体后果。患有暴食症的人常常会感到强烈的内疚、羞耻和痛苦，这会加剧这种疾病并影响他们的整体生活品质。随着世界越来越意识到心理健康问题，对有效的 BED 治疗的需求日益增长。

市场概况
预测期 2024-2028
2022 年市场规模 57132万美元
2028 年市场规模 8.5926亿美元
2023-2028 年CAGR 7.25%
成长最快的细分市场 抗忧郁药
最大的市场 北美洲

人们对暴食症及其影响的认识不断提高，导致越来越多的人寻求诊断和治疗。这推动了对 BED 疗法和干预措施的需求。对心理健康意识的持续倡导和减少饮食失调的耻辱在推动 BED 治疗市场方面发挥了至关重要的作用。专为 BED 治疗设计的药物的开发对市场成长做出了重要贡献。其中一些药物已显示出减少暴饮暴食的希望。各种治疗方法，包括认知行为疗法和辩证行为疗法，已被证明可以有效治疗暴食症。因此，对治疗服务的需求增加。

主要市场驱动因素

暴食症的流行正在推动全球暴食症治疗市场

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：全球暴食症治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（抗忧郁药、抗惊厥药、兴奋剂、其他）
    • 按配销通路（线下、线上）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图
    • 按类型
    • 按配销通路
    • 按地区

第 5 章：亚太地区暴食症治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按配销通路
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第 6 章：欧洲暴食症治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按配销通路
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 7 章：北美暴食症治疗市场前景

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按配销通路
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 8 章：南美洲暴食症治疗市场前景

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按配销通路
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 9 章：中东和非洲暴食症治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按配销通路
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：市场动态

  • 司机
  • 挑战

第 11 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 12 章：全球暴食症治疗市场：SWOT 分析

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • Viatris Inc.
  • Johnson and Johnson
  • Lupin Ltd.
  • Omeros Corp.
  • Pyramid Healthcare Inc.
  • Sumitomo Pharma Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Eli Lilly and Co
  • Tonix Pharmaceuticals Holding Corp.
  • Tryp Therapeutics Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 21708

Global Binge-eating Disorder Treatment Market was valued at USD 571.32 Million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.25% through 2028. Binge-eating disorder (BED) is a prevalent and severe eating disorder characterized by recurring episodes of consuming large quantities of food, often accompanied by a lack of control. This mental health condition affects millions of individuals worldwide, making it a significant concern for both public health and healthcare providers. As awareness of BED increases and its diagnosis becomes more precise, the global market for BED treatment has witnessed substantial growth. Binge-eating disorder is not just about overeating; it's a complex mental health condition with numerous psychological, social, and physical consequences. Those suffering from BED often feel intense guilt, shame, and distress, which can exacerbate the disorder and affect their overall quality of life. As the world becomes more conscious of mental health issues, there's a growing need for effective BED treatments.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 571.32 Million
Market Size 2028USD 859.26 Million
CAGR 2023-20287.25%
Fastest Growing SegmentAntidepressants
Largest MarketNorth America

Increased awareness about BED and its effects has led to more individuals seeking diagnosis and treatment. This has driven the demand for BED therapies and interventions. The ongoing advocacy for mental health awareness and the reduction of stigmas surrounding eating disorders have played a crucial role in driving the BED treatment market. The development of medications specifically designed for BED treatment has been a significant contributor to market growth. Some of these medications have shown promise in reducing binge-eating episodes. Various therapeutic approaches, including cognitive-behavioral therapy and dialectical behavior therapy, have proven effective in treating BED. The demand for therapy services has consequently risen.

Key Market Drivers

Prevalence of Binge-eating Disorder is Driving the Global Binge-eating Disorder Treatment Market

Over the last few decades, there has been a notable increase in the prevalence of binge-eating disorders across the globe. This surge in cases can be attributed to several factors, including increased awareness and better diagnostic criteria. Additionally, changing societal norms, lifestyle, and the increasing prevalence of obesity have contributed to the growing numbers of individuals suffering from Binge-eating Disorder. The impact of binge-eating disorder extends far beyond the individual, affecting their physical and mental health, relationships, and overall quality of life. The surge in Binge-eating disorder cases has led to a significant demand for effective treatment options. As a result, the global Binge-eating Disorder Treatment Market has experienced substantial growth. This market encompasses a range of treatment approaches, including psychotherapy, medication, self-help strategies, and more. The aim of these treatments is to help individuals with Binge-eating disorder gain control over their eating behaviours, improve their mental well-being, and reduce the risk of associated health issues, such as diabetes, heart disease, and obesity.

Cognitive-behavioural therapy (CBT) has shown to be one of the most effective treatments for Binge-eating disorder. It helps individuals identify the triggers and thought patterns that lead to binge-eating episodes and develop healthier coping strategies. In some cases, healthcare professionals may prescribe medications to manage Binge-eating disorder symptoms. Selective serotonin reuptake inhibitors (SSRIs) and antiepileptic drugs have shown promise in reducing the frequency of binge-eating episodes. Self-help books, online resources, and support groups have gained popularity as accessible and cost-effective tools for individuals with Binge-eating disorder. These resources empower individuals to take control of their condition and seek help. Healthcare providers may recommend changes in diet and exercise routines to manage BED symptoms, especially for those with comorbid obesity.

Greater Awareness is Driving the Global Binge-eating Disorder Treatment Market

Awareness of binge-eating disorder has been steadily growing over the past decade. Organizations, advocacy groups, and healthcare professionals have made significant efforts to raise awareness about BED. These initiatives focus on educating the public, healthcare providers, and policymakers about the severity of the disorder and the importance of early diagnosis and treatment. High-profile cases and media attention to BED have contributed to increased public awareness. Documentaries, news stories, and feature films often shine a light on the struggles faced by those with the disorder, helping to break down stigmas. Ongoing research into the causes and treatment of BED have helped to underscore its legitimacy as a serious mental health issue. This research has also led to the development of more effective treatment options.

The rise in awareness has had a direct impact on the global market for binge-eating disorder treatment. As more individuals seek help and professionals diagnose the condition accurately, the demand for treatment has surged. The pharmaceutical industry has responded to the growing demand for BED treatment with the development of medications specifically designed to target binge-eating behavior. These drugs can help reduce the frequency and severity of binge episodes, offering hope for individuals struggling with the disorder. Cognitive-behavioral therapy (CBT) and dialectical behavior therapy (DBT) have emerged as effective treatments for BED. As awareness of these evidence-based therapies spreads, more individuals are seeking the help of mental health professionals, further driving market growth. The rise of telehealth and digital health platforms has made it easier for individuals to access BED treatment, especially in underserved areas. Virtual therapy sessions and mobile apps have made treatment more accessible and convenient. The growth of online support communities and forums has connected individuals with BED to a network of people who understand their struggles. These platforms offer valuable peer support and resources to aid in recovery.

Key Market Challenges

Stigma and Awareness

One of the primary challenges in the BED treatment market is the persistence of stigma surrounding eating disorders, including BED. Many individuals suffering from BED do not seek help due to fear of judgment or misunderstanding of their condition. This lack of awareness not only delays diagnosis and treatment but also limits the market's potential for growth. Efforts to educate the public and healthcare professionals about BED are essential. This includes challenging the misconception that BED is simply a lack of self-control rather than a complex mental health issue. Overcoming stigma remains a significant obstacle in increasing patient engagement in treatment and driving market expansion.

Diagnosis and Screening

BED often goes undiagnosed or misdiagnosed as other eating disorders or mental health conditions, such as bulimia or depression. To effectively treat BED, early and accurate diagnosis is crucial. However, healthcare providers face challenges in implementing standardized screening and diagnostic protocols. Improving the accuracy of diagnosis through screening tools and training for healthcare professionals is a pressing issue. The development of effective diagnostic tools can enhance the treatment market by ensuring that individuals receive appropriate care.

Treatment Options

The variety of treatment options for BED remains somewhat limited compared to other eating disorders. While cognitive-behavioral therapy (CBT) has shown effectiveness in treating BED, not all patients respond well to this approach. Pharmaceutical treatments are also being explored, but the approval and market adoption of such drugs face regulatory hurdles and challenges related to safety and efficacy. Research into alternative treatment modalities, personalized therapy plans, and innovative medications is crucial to provide tailored approaches to individuals with BED. Expanding the range of available treatments is a key factor in addressing the challenges faced by the BED treatment market.

Access to Care

Access to appropriate care for BED remains a significant challenge in many regions. Financial barriers, lack of specialized treatment centers, and inadequate insurance coverage often prevent individuals from seeking the help they need. This results in underutilization of existing treatment options and hampers market growth. Addressing these challenges involves expanding access to affordable and evidence-based treatment options, increasing mental health parity in insurance policies, and developing a network of healthcare providers trained in BED treatment.

Research and Data Gaps

There is still much to learn about BED, its causes, and the most effective treatment approaches. The BED treatment market requires a robust foundation of research and data to guide advancements. Gaps in our understanding of the condition, including its genetic, neurobiological, and psychosocial underpinnings, hinder the development of targeted therapies. Investment in research and data collection is critical for overcoming these challenges. Collaboration between researchers, healthcare professionals, and pharmaceutical companies is needed to advance our knowledge of BED and develop more effective treatments.

Key Market Trends

Technological Advancements

Technological advancements have greatly improved the ability to diagnose binge-eating disorders. Machine learning algorithms and artificial intelligence (AI) tools can analyze patient data, such as medical history, food diaries, and even voice and text analysis, to detect patterns indicative of BED. These tools can assist healthcare professionals in making earlier and more accurate diagnoses, which is crucial for effective intervention. Telemedicine has become a crucial component of healthcare, especially in the context of mental health conditions like BED. Patients can now connect with therapists and healthcare providers remotely, ensuring regular check-ins and consistent support. Telemedicine apps and platforms also enable the monitoring of food intake, emotions, and progress over time. This has been a game-changer, as it allows patients to receive help from the comfort of their own homes, reducing the barriers to seeking treatment. Digital therapeutics, often in the form of smartphone apps, are revolutionizing the treatment of binge-eating disorder. These applications provide patients with tools for tracking their eating habits, setting goals, and practicing mindfulness. They often employ cognitive-behavioural therapy (CBT) techniques, which are highly effective in treating BED. Digital therapeutics not only enhance the efficacy of treatment but also improve patient engagement and adherence to therapy.

Wearable devices, such as smartwatches and fitness trackers, have integrated features that enable individuals to monitor their physical activity, heart rate, and sleep patterns. These devices can be instrumental in helping individuals with binge-eating disorder by fostering healthier lifestyles. By promoting regular exercise and improved sleep quality, they contribute to better overall well-being and can indirectly aid in the treatment process. The collection and analysis of big data have opened up new possibilities for understanding and treating BED. By analysing large datasets, researchers and healthcare providers can identify trends, risk factors, and potential treatment responses. This enables more personalized treatment plans tailored to each patient's unique needs, increasing the chances of success.

Segmental Insights

Type Insights

Based on the category of Type, Antidepressants emerged as the dominant player in the global market for Binge-eating Disorder Treatment in 2022. Antidepressants are a class of medications that have been found to be effective in treating binge-eating disorder. These drugs were initially developed to alleviate symptoms of depression, but their impact on BED is now widely recognized. Specifically, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have shown promise in reducing the frequency and severity of binge-eating episodes. Antidepressants target the brain's neurotransmitters, such as serotonin and norepinephrine, which are associated with mood regulation. By improving mood and reducing symptoms of depression and anxiety, these medications can reduce the emotional triggers that lead to binge-eating. Some antidepressants, like bupropion, can reduce appetite, making it easier for patients to control their food intake and resist the urge to binge. Antidepressants can enhance a patient's ability to resist impulsive behavior, which is often a significant factor in binge-eating episodes.

Distribution Channel Insights

The offline segment is projected to experience rapid growth during the forecast period. Offline distribution channels have historically been the cornerstone of the Binge-eating Disorder treatment market, with healthcare professionals, clinics, and hospitals playing a crucial role in patient assessment and treatment. Offline distribution channels allow for a patient-centric approach to treatment, ensuring that the individual's unique needs and circumstances are at the forefront of the treatment plan. Seeking treatment for a mental health disorder can still carry stigma in many societies. Offline channels often provide a discreet and confidential setting for individuals to receive treatment without fear of judgment or disclosure.

Regional Insights

North America emerged as the dominant player in the global Binge-eating Disorder Treatment market in 2022, holding the largest market share in terms of value. North America, particularly the United States and Canada, has some of the highest prevalence rates of binge-eating disorder in the world. This has led to a greater demand for effective treatments and a more extensive market for pharmaceutical companies and treatment providers.

Key Market Players

Viatris Inc.

Johnson and Johnson

Lupin Ltd.

Omeros Corp.

Pyramid Healthcare Inc.

Sumitomo Pharma Co. Ltd.

Takeda Pharmaceutical Co. Ltd.

Eli Lilly and Co

Tonix Pharmaceuticals Holding Corp.

Tryp Therapeutics Inc.

Report Scope:

In this report, the Global Binge-eating Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Binge-eating Disorder Treatment Market, By Type:

  • Antidepressants
  • Anticonvulsants
  • Stimulants
  • Others

Binge-eating Disorder Treatment Market, By Distribution Channel:

  • Offline
  • Online

Binge-eating Disorder Treatment Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Binge-eating Disorder Treatment Market.

Available Customizations:

  • Global Binge-eating Disorder Treatment market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Binge-eating Disorder Treatment Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type (Antidepressants, Anticonvulsants, Stimulants, Others)
    • 4.2.2. By Distribution Channel (Offline, Online)
    • 4.2.3. By Region
    • 4.2.4. By Company (2022)
  • 4.3. Market Map
    • 4.3.1. By Type
    • 4.3.2. By Distribution Channel
    • 4.3.3. By Region

5. Asia Pacific Binge-eating Disorder Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Distribution Channel
    • 5.2.3. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Binge-eating Disorder Treatment Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Type
        • 5.3.1.2.2. By Distribution Channel
    • 5.3.2. India Binge-eating Disorder Treatment Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Type
        • 5.3.2.2.2. By Distribution Channel
    • 5.3.3. Australia Binge-eating Disorder Treatment Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Type
        • 5.3.3.2.2. By Distribution Channel
    • 5.3.4. Japan Binge-eating Disorder Treatment Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Type
        • 5.3.4.2.2. By Distribution Channel
    • 5.3.5. South Korea Binge-eating Disorder Treatment Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Type
        • 5.3.5.2.2. By Distribution Channel

6. Europe Binge-eating Disorder Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Binge-eating Disorder Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Germany Binge-eating Disorder Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Spain Binge-eating Disorder Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Distribution Channel
    • 6.3.4. Italy Binge-eating Disorder Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Distribution Channel
    • 6.3.5. United Kingdom Binge-eating Disorder Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Distribution Channel

7. North America Binge-eating Disorder Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Binge-eating Disorder Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. Mexico Binge-eating Disorder Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. Canada Binge-eating Disorder Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Distribution Channel

8. South America Binge-eating Disorder Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Binge-eating Disorder Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. Argentina Binge-eating Disorder Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Colombia Binge-eating Disorder Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Distribution Channel

9. Middle East and Africa Binge-eating Disorder Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Binge-eating Disorder Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Saudi Arabia Binge-eating Disorder Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. UAE Binge-eating Disorder Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Distribution Channel

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Binge-eating Disorder Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Viatris Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Johnson and Johnson
  • 14.3. Lupin Ltd.
  • 14.4. Omeros Corp.
  • 14.5. Pyramid Healthcare Inc.
  • 14.6. Sumitomo Pharma Co. Ltd.
  • 14.7. Takeda Pharmaceutical Co. Ltd.
  • 14.8. Eli Lilly and Co
  • 14.9. Tonix Pharmaceuticals Holding Corp.
  • 14.10. Tryp Therapeutics Inc.

15. Strategic Recommendations

16. About Us & Disclaimer